Tecentriq 1200 mg/20 mL Concentrate for Solution for Infusion by Roche is a groundbreaking immunotherapy medication containing Atezolizumab, a monoclonal antibody designed to target and block the PD-L1 protein. Tecentriq 1200 mg is used in the treatment of various types of advanced and metastatic cancers, including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and urothelial carcinoma (bladder cancer).
Tecentriq 1200 mg/20 mL Atezolizumab works by restoring the immune system’s ability to detect and destroy cancer cells. It helps prevent cancer cells from evading immune surveillance, leading to improved survival rates and better treatment outcomes. As part of the modern immuno-oncology approach, Tecentriq has revolutionized cancer care, providing hope to patients with previously limited treatment options.
🔥 Key Benefits & Uses of Tecentriq 1200 mg Atezolizumab:
- Non-Small Cell Lung Cancer (NSCLC): Tecentriq 1200 mg is approved for first-line and maintenance treatment in combination with chemotherapy or other targeted therapies for advanced NSCLC.
- Small Cell Lung Cancer (SCLC): Tecentriq 1200 mg is a standard treatment option for extensive-stage SCLC when combined with chemotherapy, improving overall survival.
- Triple-Negative Breast Cancer (TNBC): Tecentriq 1200 mg is used with nab-paclitaxel for unresectable, locally advanced, or metastatic PD-L1-positive TNBC.
- Urothelial Carcinoma (Bladder Cancer): Tecentriq 1200 mg is indicated for patients with locally advanced or metastatic urothelial carcinoma, especially those ineligible for cisplatin-based chemotherapy.
- PD-L1 Inhibition: Tecentriq 1200 mg Atezolizumab selectively binds to PD-L1, blocking its interaction with PD-1 and B7.1 receptors, reactivating T-cells, and enhancing anti-tumor immunity.
- Immunotherapy Innovation: Tecentriq 1200 mg is part of the growing class of checkpoint inhibitors revolutionizing cancer treatment.
💊 How to Use Tecentriq 1200 mg Atezolizumab – Infusion Administration:
- Dosage: Tecentriq 1200 mg is administered as an intravenous infusion over approximately 60 minutes, typically every 2 to 4 weeks depending on the treatment plan.
- Administration: Tecentriq 1200 mg/20 mL is diluted in a sodium chloride solution before infusion, under the supervision of a qualified healthcare professional.
- Treatment Duration: Long-term treatment may be required based on disease progression and patient tolerance.
🧊 Storage Instructions:
- Store Tecentriq 1200 mg vials in a refrigerator (2°C to 8°C).
- Do not freeze or shake.
- Protect from light and keep in the original packaging.
⚠️ Potential Side Effects of Tecentriq 1200 mg Atezolizumab:
- Fatigue and weakness.
- Nausea, decreased appetite.
- Immune-related side effects: pneumonitis, hepatitis, colitis, nephritis, and endocrinopathies.
- Infusion-related reactions.
Seek immediate medical attention for severe immune-related adverse events.
🌍 Why Choose Tecentriq 1200 mg Atezolizumab by Roche?
- Manufactured by Roche, a leading innovator in oncology and immunotherapy.
- Approved by global health authorities for lung, breast, and bladder cancer treatment.
- Significant survival benefits for patients with advanced cancers.
- Part of personalized cancer immunotherapy protocols.
- Proven to enhance quality of life and extend survival in clinical trials.
✅ Real Patient Reviews:
“Tecentriq 1200 mg gave me a second chance. I was diagnosed with advanced lung cancer, but this immunotherapy slowed the progression and gave me hope.” – Patient Testimonial
🔗 Official Resource:
Roche Tecentriq Official Page – Comprehensive prescribing information and clinical trial data.
Değerlendirmeler
Henüz değerlendirme yapılmadı.